Search
belinostat (Beleodaq)
Indications:
- refractory peripheral T-cell lymphoma [1]
Adverse effects:
- nausea/vomiting
- fever
- anemia
Mechanism of action:
- inhibits histone deacetylase [2]
General
antineoplastic agent (chemotherapeutic agent)
enzyme inhibitor
Database Correlations
PUBCHEM cid=6918638
References
- FDA News Release. July 3, 2014
FDA approves Beleodaq to treat rare, aggressive form of
non-Hodgkin lymphoma.
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm403929.htm
- PubChem: 6918638